We are live on ! Find out more
JY

Jeff Yass Susquehanna International Group

AUM $1.28T
1-Year Est. Return 58.89%
 

Jeff Yass is a co-founder of Susquehanna International Group (SIG), a major global trading and market-making firm. SIG is known for options expertise, quantitative trading, and a training culture grounded in probabilistic decision-making. Yass’s firm is influential across derivatives markets even though it is less of a traditional long-only stock-picking franchise.

This Fund
S&P 500
This Quarter Est. Return
+11.22%
1 Year Est. Return
+58.89%
3 Year Est. Return
+161.44%
5 Year Est. Return
+153.95%
10 Year Est. Return
+545.54%
AUM
$347B
AUM Growth
+$49B
Cap. Flow
+$12.7B
Cap. Flow %
3.67%
Top 10 Hldgs %
25.82%
Holding
11,328
New
1,232
Increased
3,827
Reduced
4,449
Closed
1,709

Top Buys

Rank Stock Value
1
BA icon
Boeing
BA
+$1.33B
2
GOOGL icon
Alphabet (Google) Class A
GOOGL
+$781M
3
TSLA icon
Tesla
TSLA
+$468M
4
QQQ icon
Invesco QQQ Trust
QQQ
+$467M
5
HD icon
Home Depot
HD
+$344M

Sector Composition

Rank Sector Weight
1 Technology 2.2%
2 Consumer Discretionary 1.94%
3 Communication Services 1.89%
4 Healthcare 1.12%
5 Financials 1.12%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
NVIV
9501
DELISTED
InVivo Therapeutics Holdings Corp
NVIV
$10K ﹤0.01%
+57
New +$14.2K
GSAT icon
9502
Globalstar
GSAT
$10.6B
$9K ﹤0.01%
1,167
-4,299
-79% -$26K
INDP icon
9503
Indaptus Therapeutics
INDP
$145M
$9K ﹤0.01%
8
-1
-11% -$1.38K
SNES icon
9504
SenesTech
SNES
$6.45M
0
TGB
9505
Trekor Metals
TGB
$3.48B
$9K ﹤0.01%
19,054
+5,040
+36% +$2.13K
VTGN icon
9506
VistaGen Therapeutics
VTGN
$11M
$9K ﹤0.01%
456
-16
-3% -$404
CSCI
9507
CALL
DELISTED
COSCIENS Biopharma Inc. Common Stock
CSCI
$9K ﹤0.01%
100
-167
-63% -$15.6K
PAVMZ
9508
DELISTED
PAVmed Inc. Series Z Warrant
PAVMZ
$9K ﹤0.01%
23,195
-86,353
-79% -$27.1K
DMK
9509
DELISTED
DMK Pharmaceuticals Corporation Common Stock
DMK
$9K ﹤0.01%
190
-535
-74% -$25.9K
SQBG
9510
DELISTED
Sequential Brands Group, Inc.
SQBG
$9K ﹤0.01%
+669
New +$9.73K
FBRX icon
9511
PUT
Forte Biosciences
FBRX
$1.63B
$8K ﹤0.01%
40
-178
-82% -$40.3K
INUV icon
9512
Inuvo
INUV
$11.8M
$8K ﹤0.01%
2,712
-911
-25% -$2.56K
STAB
9513
DELISTED
Statera Biopharma, Inc. Common Stock
STAB
$8K ﹤0.01%
13,922
-7,121
-34% -$5.26K
TKKSR
9514
DELISTED
TKK Symphony Acquisition Corporation Right
TKKSR
$8K ﹤0.01%
+33,645
New +$8.62K
SMTA
9515
CALL
DELISTED
Spirit MTA REIT Common Shares of Beneficial Interest
SMTA
$8K ﹤0.01%
10,500
IGC icon
9516
IGC Pharma
IGC
$31.5M
$7K ﹤0.01%
10,794
-46,540
-81% -$38.1K
OTLK icon
9517
Outlook Therapeutics
OTLK
$155M
$7K ﹤0.01%
585
-243
-29% -$5.66K
TARA icon
9518
Protara Therapeutics
TARA
$235M
$7K ﹤0.01%
410
-1,491
-78% -$17.1K
THM
9519
International Tower Hill Mines
THM
$738M
$7K ﹤0.01%
12,091
-16,232
-57% -$8.63K
VIVS
9520
VivoSim Labs
VIVS
$3.9M
$7K ﹤0.01%
81
-53
-40% -$4.96K
AMPE
9521
CALL
DELISTED
Ampio Pharmaceuticals Inc.
AMPE
$7K ﹤0.01%
43
-119
-73% -$15.4K
ENT
9522
DELISTED
Global Eagle Entertainment Inc.
ENT
$7K ﹤0.01%
557
-2,166
-80% -$29.8K
CORV
9523
PUT
DELISTED
Correvio Pharma Corp. Ordinary Shares (Canada)
CORV
$7K ﹤0.01%
+16,300
New +$27.1K
IDXG
9524
DELISTED
Interpace Biosciences, Inc. Common Stock
IDXG
$7K ﹤0.01%
1,486
-1,434
-49% -$9.28K
WYY icon
9525
WidePoint Corp
WYY
$94.6M
$6K ﹤0.01%
+1,437
New +$5.19K

Similar funds

Jeff Yass's Q4 2019 Portfolio in Review

As of Q4 2019, Jeff Yass held 11,328 positions worth $347B, up 16% from $298B the previous quarter. Its ten largest holdings account for 26% of the portfolio.

Jeff Yass deployed $12.7B of net new capital in Q4 2019, opening 1,232 new positions and adding to 3,827 existing holdings. Its largest new stake was Invesco Zacks Mid-Cap ETF: 1,353,476 shares worth $104M.

By sector, the portfolio is most concentrated in Technology at 2.2% of assets, up from 2.1% a quarter earlier, followed by Consumer Discretionary and Communication Services.

On the sell side, the largest reduction was Amazon, an estimated $1.36B trimmed.

  • Jeff Yass's largest Q4 2019 buy was Invesco Zacks Mid-Cap ETF: 1,353,476 shares worth $104M.
  • Jeff Yass added most to Boeing in Q4 2019, an estimated $1.33B increase.
  • Jeff Yass's biggest Q4 2019 reduction was Amazon, cutting an estimated $1.36B.
  • Jeff Yass fully exited Celgene Corp in Q4 2019, selling an estimated $164M.
  • Jeff Yass's ten largest holdings make up 26% of its $347B portfolio in Q4 2019.
  • Jeff Yass opened 1,232 new positions and closed 1,709 in Q4 2019.
  • Jeff Yass's portfolio value rose 16% quarter-over-quarter to $347B.

Based on Susquehanna International Group's 13F filing for Q4 2019, filed 14 Feb 2020.